Ocrelizumab extended‐interval dosing in multiple sclerosis during <scp>SARS‐CoV</scp>‐2 pandemic: a real‐world experience
Simone Guerrieri(Vita-Salute San Raffaele University), Matteo Azzimonti(Vita-Salute San Raffaele University), Angela Genchi(Vita-Salute San Raffaele University), Lucia Moiola(Vita-Salute San Raffaele University), Irene Gattuso(Vita-Salute San Raffaele University), Giulia Rugarli(Istituti di Ricovero e Cura a Carattere Scientifico), Ilaria Cetta(Vita-Salute San Raffaele University), Agostino Nozzolillo(IRCCS Ospedale San Raffaele), Chiara Zanetta(IRCCS Ospedale San Raffaele), Maria A. Rocca(Vita-Salute San Raffaele University), Massimo Filippi(Vita-Salute San Raffaele University), Chiara Bucca(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 29
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k